2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
Did you get a chance to watch the educational symposium on nodular calcium at TCT 2022? If you missed it, we’ve got you covered!
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Clinical Data,
Shockwave C2,
Coronary Conferences,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes
Despite often being more challenging to treat, female PCI patients are under-represented in published data, with no dedicated prospective studies performed on this population. To address this unmet need, Shockwave is launching EMPOWER CAD, the first prospective, female-only study of coronary interventions.
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Clinical Data,
Shockwave C2,
Coronary Conferences,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes
At Shockwave, we are committed to doing everything we can to narrow the PCI gender inequality gap starting with clinical evidence presented at SCAI 2022 where Coronary IVL demonstrated sustained long term clinical outcomes and excellent safety in both women and men suggesting first line use of Coronary IVL for plaque modification in female patients with calcified lesions.
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Female vs. Male Outcomes
Leading female interventionalists came together at SCAI 2022 to discuss what they are most excited about in the interventional space today, share key takeaways from SCAI, and discuss the female focused initiatives that will help bridge the PCI gap in gender disparities going forward. From the JSCAI expert consensus, gender focused clinical evidence highlights at SCAI, and future research to SCAI WIN initiatives, these female leaders covered it all.
Listen to the podcast with Dr. Dawn Abbott, MD, Rhode Island Hospital, Dr. Suzanne Baron, MD, Lahey Hospital and Medical Center, Dr. Alexandra Lansky, MD, Yale University School of Medicine, Yale University and Dr. Nadia Sutton, MD, University of Michigan.
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Clinical Data,
Shockwave C2,
Coronary Conferences,
ChalkTalk Podcast,
Female vs. Male Outcomes
With calcium being as hot of a topic as ever in the interventional community, now is the time to invest in research to better understand its impact across patient populations and trends in modification techniques. Shockwave, in partnership with SCAI, is sponsoring a $50,000 grant for research that improves current understanding of calcified lesions. This one-time grant is eligible for SCAI members within 10 years of completing an Interventional Cardiology fellowship. Research must last 1-year and focus within one of the two following areas:
- Disparities in the treatment of calcified lesions (e.g. gender, race/gender, age)
- Recent treatment and outcome trends in coronary calcium modification (per NCDR)
Applicants are encouraged to access the application instructions at this link. Submissions open May 21, 2022 and close August 21, 2022. Awardees will be notified in September 2022.
We hope this grant improves knowledge & understanding of calcified lesions and further informs us of gender, race and age disparities in coronary calcium modification outcomes.
SCAI Early Career Research Grants presented by Dr Sunil Rao at SCAI 2022
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Female vs. Male Outcomes
In episode #9 of the ChalkTalk podcast, we speak with Alexandra Lansky, MD, FACC, FAHA, FSCAI, FESC, Professor of Medicine in Cardiology, and Director of Yale Cardiovascular Clinical Research Program at Yale University School of Medicine in New Haven, Connecticut, about her recent gender analyses at TCT21 and SCAI22, in which she presented the respective 30-day and 1-year outcomes broken out by women vs men that were enrolled in the Disrupt CAD clinical program.
Dr. Lansky shares the genesis of the analysis - previous research showing that female atherectomy patients have an increased risk for angiographic complications than their male counterparts,[i] and sheds light on what makes coronary IVL unique from a safety perspective. She concludes by discussing the recent publication of SCAI’s “Expert Consensus Statement on Sex-Specific Consideration in Myocardial Revascularization” in JSCAI, which referenced the role of IVL in female patients. The SCAI guidelines concluded, “while additional evidence is needed, these results taken in the context of outcomes with atherectomy devices suggest that IVL may emerge as a first-line therapy for plaque modification of calcified lesions in women specifically.”
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
ChalkTalk Podcast,
Female vs. Male Outcomes